Salarius Pharmaceuticals, Inc(NASDAQ:SLRX) 
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. The company's lead candidate is Seclidemstat (SP-2577), which is in Phase I/II clinical trial for the treatment of advanced solid tumors, including prostate, breast, and ...
Share this website to your friends
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-04
P
O 10.79
H 11.69
L 10.34
C 10.64
V 34,516
10EMA 10.64
20EMA 10.64
60EMA 10.64
120EMA 10.64
250EMA 10.64